(PHVS) Pharvaris N.V. Business Model Canvas Research

Allergists and immunologists are core partners for Pharvaris N.V. in hereditary angioedema, a rare disease affecting about 1 in 50,000 people. They diagnose most patients and guide the 2 main HAE treatment paths, so their input helps set trial endpoints, refine study design, and speed future adoption.

• Key opinion leaders shape endpoints
• They improve trial design and education
• They support clinician uptake

Pharvaris N.V., founded in 2015, relies on investors and other capital-market backers to fund its multi-year R&D pipeline because it still has no approved product revenue. This support is the core financing link for a clinical-stage company, and it helps keep development running while the company works through late-stage trials and regulatory steps.

• Clinical-stage, no product sales yet
• External capital funds R&D spend
• Public investors back long timelines
• Funding is key until approval

Pharvaris N.V. must shape HAE trials to orphan-disease rules, using focused endpoints and small samples; HAE is rare, affecting about 1 in 50,000 people, so regulators expect tight evidence packages, not broad-population studies. That same plan also supports future pricing and reimbursement talks by linking clinical benefit to a clear unmet-need case.

• Use HAE-specific endpoints and small cohorts.
• Build evidence for regulator and payer review.
• Support orphan pricing and reimbursement cases.

Pharvaris N.V. prioritizes PHA121, PHVS416, and PHVS719 by comparing efficacy, safety, and dosing data from each readout. Those results decide how capital shifts between on-demand and prophylactic HAE programs, and they set which asset can move fastest toward registration.

• Compare clinical data across all three assets
• Use readouts to direct capital allocation
• Advance the fastest path to registration

Pharvaris N.V. relies on clinical and regulatory expertise to design rare-disease trials, watch safety, and file approvals for programs like deucrictibant in hereditary angioedema. This know-how sits in its internal team and advisor network, and it lets the company run multiple studies at once while staying pre-revenue in 2025.

• Designs rare-disease trials
• Manages safety and filings
• Supports parallel programs

Pharvaris N.V. is headquartered in Leiden, the Netherlands, and its international footprint spans 3 countries: the Netherlands, Switzerland, and the United States. That setup supports clinical operations across major biopharma hubs and helps the company stay close to investors and trial partners in Europe and the U.S.

• Head office: Leiden, Netherlands
• Operating base: 3 countries
• Supports clinical development and investor access

Pharvaris N.V. targets hereditary angioedema, which affects about 1 in 10,000 to 1 in 50,000 people, with many current therapies given by injection or infusion. A non-injectable small-molecule option could cut treatment burden, improve ease of use, and help patients and caregivers manage attacks more simply.

• Oral, not injectable
• Lower caregiver burden
• Fits routine use better

Pharvaris N.V. is built around rare diseases, led by hereditary angioedema (HAE), a condition affecting about 1 in 50,000 people. That narrow focus supports tighter R&D spend, faster physician education, and orphan-drug economics with smaller patient pools but higher pricing power.

• Lead focus: HAE

• Rare-patient market: ~1 in 50,000

• Supports orphan-drug value

HAE patient groups are central to Pharvaris N.V.’s outreach because rare-disease trust drives uptake; HAE affects about 1 in 50,000 people, so small communities can shape awareness, trial enrollment, and feedback on treatment experience. In 2025, patient groups still act as a key channel for education on symptoms, diagnosis delays, and unmet need.

• Build trust in rare-disease communities
• Support trial awareness and enrollment
• Improve disease education and feedback

Pharvaris N.V. will need fast medical information and safety replies on dosing, attack management, and adverse events, because hereditary angioedema care depends on rapid, clear guidance. Late-stage programs also raise pharmacovigilance load, so responsive channels can support both patients and clinicians.

• Clear dosing and attack-use guidance

• 24/7 safety and adverse-event intake

• Better trust as trials advance

If approved, Pharvaris N.V.’s HAE therapies would likely be dispensed through specialty pharmacies, the standard channel for rare-disease drugs. This model supports controlled distribution, adherence support, and patient coordination for complex therapies that often need prior authorization and ongoing refill tracking.

• Standard for rare-disease launches
• Supports adherence services
• Improves patient coordination

Pharvaris N.V. uses its corporate website, press releases, and investor decks to report milestones while it stays pre-commercial and has no product revenue in 2025. These channels help recruit talent, support financing, and keep the company visible to investors as it advances its pipeline.

• Website: milestone hub
• Press releases: trial updates
• Investor materials: financing support

Severe hereditary angioedema attacks can drive emergency evaluation, airway monitoring, and rescue treatment, so hospitals and urgent care sites sit at the center of diagnosis and escalation. In the U.S., HAE affects about 1 in 50,000 people, and the global market for HAE therapies was valued at roughly $3 billion in 2025, making pathway design and specialist referral a real commercial lever for Pharvaris N.V.

• Rescue care and airway triage
• Diagnosis plus specialist referral
• Education for ED and urgent care teams

In rare diseases, payers and integrated delivery systems control access, so Pharvaris N.V. must prove clear clinical benefit, lower flare burden, and limited use. Their coverage rules drive revenue realization because even a strong therapy needs prior authorization, step edits, and formulary placement before patients can start.

Rare-disease drug access can hinge on one decision by a health plan or IDN, so evidence on hospital use, rescue meds, and total cost of care matters most.

• Focus on clinical benefit
• Limit utilization impact
• Win formulary access
• Protect revenue realization

Pharvaris N.V. must fund filings, audits, pharmacovigilance, and quality systems in every target market, so this cost line is fixed and recurring. It usually rises as programs near approval, when inspection prep, safety reporting, and CMC work intensify.

• Fixed in every market
• Grows near approval
• Covers audits and safety

General and administrative overhead at Pharvaris N.V. covers headcount, facilities, legal, finance, and public-company reporting, so it stays on even when pipeline spend shifts. With teams and operations in the Netherlands, Switzerland, and the United States, coordination and compliance add a real fixed-cost drag for a small biotech.

That makes G&A a meaningful burn item, because it scales with company size, not near-term product sales.

• Recurring headcount and office costs
• Legal, finance, and audit support
• Public-company reporting burden
• Cross-border coordination in 3 countries
• High fixed burn for a small biotech

If Pharvaris out-licenses assets, it can earn royalties on net sales, a recurring stream that scales without building sales teams in every market. In biotech, royalty rates in licensing deals often land in the 5% to 15% range of net sales, so even modest product sales can turn into durable income.

• Recurring, sales-linked income
• No direct market build-out needed
• Standard biotech deal structure

In FY2025, Pharvaris N.V. was still clinical-stage, so grant or subsidy funding matters more as cost support than as a core revenue line. In rare-disease R&D, public programs are usually small versus future product sales, but they can help fund pre-approval work and reduce cash burn.

• Offsets early R&D costs
• Useful before approval
• Usually smaller than product revenue
• Fits rare-disease innovation programs